These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 31797350)

  • 1. A high level of serum neopterin is associated with rapidly progressive interstitial lung disease and reduced survival in dermatomyositis.
    Peng QL; Zhang YM; Liang L; Liu X; Ye LF; Yang HB; Zhang L; Shu XM; Lu X; Wang GC
    Clin Exp Immunol; 2020 Mar; 199(3):314-325. PubMed ID: 31797350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody.
    Jiang L; Wang Y; Peng Q; Shu X; Wang G; Wu X
    Clin Rheumatol; 2019 Jun; 38(6):1655-1663. PubMed ID: 30739212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
    Fujisawa T; Hozumi H; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Suda T
    J Rheumatol; 2019 Aug; 46(8):935-942. PubMed ID: 31092718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease.
    Ye Y; Fu Q; Wang R; Guo Q; Bao C
    J Clin Lab Anal; 2019 Oct; 33(8):e22978. PubMed ID: 31301087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis.
    Sakamoto S; Okamoto M; Kaieda S; Fujimoto K; Nagata S; Tominaga M; Nakamura M; Zaizen Y; Nouno T; Koga T; Kawayama T; Kuwana M; Ida H; Hoshino T
    Respir Investig; 2018 Nov; 56(6):464-472. PubMed ID: 30150008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic evaluation of serum osteopontin in patients with anti-MDA5 antibody-positive dermatomyositis associated interstitial lung disease.
    Gao Y; Zhao Q; Xie M; Yan X; Li Y; Zhang X; Wu H; Dai J; Cao M; Cai H
    Cytokine; 2020 Nov; 135():155209. PubMed ID: 32738770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated serum B-cell activator factor levels predict rapid progressive interstitial lung disease in anti-melanoma differentiation associated protein 5 antibody positive dermatomyositis.
    Shi Y; You H; Liu C; Qiu Y; Lv C; Zhu Y; Xu L; Wang F; Zhang M; Tan W
    Orphanet J Rare Dis; 2024 Apr; 19(1):170. PubMed ID: 38637830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased Levels of Soluble CD206 Associated with Rapidly Progressive Interstitial Lung Disease in Patients with Dermatomyositis.
    Shen YW; Zhang YM; Huang ZG; Wang GC; Peng QL
    Mediators Inflamm; 2020; 2020():7948095. PubMed ID: 33192174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease.
    Enomoto Y; Suzuki Y; Hozumi H; Mori K; Kono M; Karayama M; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inui N; Suzuki D; Ogawa N; Nakashima R; Mimori T; Iwashita T; Suda T
    Arthritis Res Ther; 2017 Jan; 19(1):9. PubMed ID: 28103926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum neopterin as well as ferritin, soluble interleukin-2 receptor, KL-6 and anti-MDA5 antibody titer provide markers of the response to therapy in patients with interstitial lung disease complicating anti-MDA5 antibody-positive dermatomyositis.
    Nishioka A; Tsunoda S; Abe T; Yoshikawa T; Takata M; Kitano M; Matsui K; Nakashima R; Hosono Y; Ohmura K; Mimori T; Sano H
    Mod Rheumatol; 2019 Sep; 29(5):814-820. PubMed ID: 30449228
    [No Abstract]   [Full Text] [Related]  

  • 11. Relevance of interferon-gamma in pathogenesis of life-threatening rapidly progressive interstitial lung disease in patients with dermatomyositis.
    Ishikawa Y; Iwata S; Hanami K; Nawata A; Zhang M; Yamagata K; Hirata S; Sakata K; Todoroki Y; Nakano K; Nakayamada S; Satoh M; Tanaka Y
    Arthritis Res Ther; 2018 Oct; 20(1):240. PubMed ID: 30367666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis.
    Kobayashi N; Takezaki S; Kobayashi I; Iwata N; Mori M; Nagai K; Nakano N; Miyoshi M; Kinjo N; Murata T; Masunaga K; Umebayashi H; Imagawa T; Agematsu K; Sato S; Kuwana M; Yamada M; Takei S; Yokota S; Koike K; Ariga T
    Rheumatology (Oxford); 2015 May; 54(5):784-91. PubMed ID: 25288783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of rapidly progressive interstitial lung disease and prognosis in Chinese patients with anti-melanoma differentiation-associated gene 5-positive dermatomyositis.
    Li M; Zhao X; Liu B; Zhao Y; Li X; Ma Z; Yang Q
    Front Immunol; 2023; 14():1209282. PubMed ID: 37691917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD.
    Horiike Y; Suzuki Y; Fujisawa T; Yasui H; Karayama M; Hozumi H; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Ogawa N; Suda T
    Rheumatology (Oxford); 2019 Dec; 58(12):2143-2152. PubMed ID: 31143953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Utility of YKL-40 in Polymyositis/dermatomyositis-associated Interstitial Lung Disease.
    Hozumi H; Fujisawa T; Enomoto N; Nakashima R; Enomoto Y; Suzuki Y; Kono M; Karayama M; Furuhashi K; Murakami A; Inui N; Nakamura Y; Mimori T; Suda T
    J Rheumatol; 2017 Sep; 44(9):1394-1401. PubMed ID: 28711881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum Krebs von den Lungen-6 concentrations reflect severity of anti-melanoma differentiation-associated protein 5 antibody positive dermatomyositis associated interstitial lung disease.
    Zhu Y; Wang L; Sun Y; Wang J; Lv C; You H; Xu L; Wang F; Zhang M; Tan W; Ke Y
    Clin Exp Rheumatol; 2022 Feb; 40(2):292-297. PubMed ID: 34874831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of radiological patterns of HRCT and their association with macrophage activation in dermatomyositis.
    Zuo Y; Ye L; Liu M; Li S; Liu W; Chen F; Lu X; Gordon P; Wang G; Shu X
    Rheumatology (Oxford); 2020 Oct; 59(10):2829-2837. PubMed ID: 32065646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis.
    Chen Z; Cao M; Plana MN; Liang J; Cai H; Kuwana M; Sun L
    Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1316-24. PubMed ID: 23908005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of cytokines and chemokines and association with clinical severity of dermatomyositis and clinically amyopathic dermatomyositis.
    Chen M; Quan C; Diao L; Xue F; Xue K; Wang B; Li X; Zhu X; Zheng J; Cao H
    Br J Dermatol; 2018 Dec; 179(6):1334-1341. PubMed ID: 30101523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated carcinoembryonic antigen predicts rapidly progressive interstitial lung disease in clinically amyopathic dermatomyositis.
    Zhu D; Qiao J; Tang S; Pan Y; Li S; Yang C; Fang H
    Rheumatology (Oxford); 2021 Aug; 60(8):3896-3903. PubMed ID: 33398346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.